A Multiple Treatment Comparison of Eleven Disease-Modifying Drugs Used for Multiple Sclerosis.

about

A Multiple Treatment Comparison of Eleven Disease-Modifying Drugs Used for Multiple Sclerosis.

Item

http://www.wikidata.org/entity/Q50111623

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

A Multiple Treatment Compariso ...... s Used for Multiple Sclerosis.

@en

A Multiple Treatment Compariso ...... s Used for Multiple Sclerosis.

@nl

type

Item

label

A Multiple Treatment Compariso ...... s Used for Multiple Sclerosis.

@en

A Multiple Treatment Compariso ...... s Used for Multiple Sclerosis.

@nl

prefLabel

A Multiple Treatment Compariso ...... s Used for Multiple Sclerosis.

@en

A Multiple Treatment Compariso ...... s Used for Multiple Sclerosis.

@nl

P1476

A Multiple Treatment Compariso ...... s Used for Multiple Sclerosis.

@en

P2093

Elisabeth Couto

http://www.w3.org/2001/XMLSchema#string

Marianne Klemp

http://www.w3.org/2001/XMLSchema#string

Tove Ringerike

http://www.w3.org/2001/XMLSchema#string

Vida Hamidi

http://www.w3.org/2001/XMLSchema#string

P2860

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

Defining the clinical course of multiple sclerosis: the 2013 revisions.

Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis

Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

Multiple sclerosis

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

P304

88-105

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.14740/JOCMR3168W

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29317954

http://www.w3.org/2001/XMLSchema#string

P932

5755648

http://www.w3.org/2001/XMLSchema#string